Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is used as a therapeutic approach for primary immunodeficiencies (PIDs). The best outcomes have been achieved with HLA-matched donors, but when a matched donor is not available, a haploidentical or mismatched unrelated donor (mMUD) can be useful. Various strategies are used to mitigate the risk of graft-versus-host disease (GvHD) and rejection associated with such transplants. Objective: We sought to evaluate the outcomes of haploidentical or mMUD HSCT after depleting GvHD-causing T-cell receptor (TCR) ab CD3 1 cells from the graft. Methods: CD3
1 TCRab 1 /CD19 1 depleted grafts were given in conditioned (except 3) children with PIDs. Treosulfan (busulfan in 1 patient), fludarabine, thiotepa, and anti-thymocyte globulin or alemtuzumab conditioning were used in 77% of cases, and all but 4 received GvHD prophylaxis. Results: Twenty-five patients with 12 types of PIDs received 26 HSCTs. Three underwent transplantation for refractory GvHD that developed after the first cord transplantation. At a median follow-up of 20.8 months (range, 5 month-3.3 years), 21 of 25 patients survived and were cured of underlying immunodeficiency. Overall and event-free survival at 3 years were 83.9% and 80.4%, respectively. Cumulative incidence of grade II to IV acute GvHD was 22% 6 8.7%. No case of visceral or chronic GvHD was seen. Cumulative incidences of graft failure, cytomegalovirus, and/or adenoviral infections and transplant-related mortality at 1 year were 4.2% 6 4.1%, 58.8% 6 9.8%, and 16.1% 6 7.4%, respectively. Patients undergoing transplantation with systemic viral infections had poor survival in comparison with those with absent or resolved infections (33.3% vs 100%).
Conclusion: CD3
1 TCRab 1 and CD19 1 cell-depleted haploidentical or mMUD HSCT is a practical and viable alternative for children with a range of PIDs. Hematopoietic stem cell transplantation (HSCT) is curative for many primary immunodeficiencies (PIDs); however an HLAmatched donor might not be available, and in this case a mismatch related (haploidentical) donor or mismatched unrelated donor (mMUD) can be useful. Because of significant HLA donorrecipient disparities, these options bring higher rates of graft failure and graft-versus-host disease (GvHD), which contribute to poor survival. 1 Various approaches have been tried to mitigate these risks, such as T-cell depletion, 2 T-and B-cell depletion, 3 megadose CD34 1 cell selection, 4 and, recently, posttransplantation cyclophosphamide 5 and CD3 1 T-cell receptor (TCR) ab 6, 7 and naive T-cell 8 depletion. Commonly used methods, such as CD34 1 selection, decrease the risk of GvHD, but the risk of delayed viral clearance and immune recovery remains. 9 Graft manipulation by depleting GvHD-inducing a/b receptor T cells offers a reduction in GvHD while retaining populations of g/d receptor T cells 10 in [15] [16] [17] disorders. Using this technique to transplant from an immediately available haploidentical donor seems appealing, but more data are required not only on survival but also on morbidities, long-term immune reconstitution, and cost effectiveness in comparison with other modalities of transplantation. We report the outcome of this method in 25 patients with PIDs undergoing mismatched HSCT when a suitably matched donor was not available.
METHODS
A retrospective review of consecutive patient records was performed. Pretransplantation data were collected regarding patients' demographics, infections, donor-recipient matching, and conditioning regimens. Posttransplantation data were collected on engraftment, transfusion requirement, immune reconstitution, GvHD, and infection. Chimerism analysis was performed by using PCR-based amplification of short tandem repeat sequences. Various cell types in blood were assessed by using flow cytometry with mAbs against lineage-specific surface molecules (T cells, CD3 
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Patients
Patients' demographics and transplantation characteristics are shown in Table I . Twenty-five patients underwent 26 transplantations at the 2 HSCT centers for PIDs in the United Kingdom (Great North Children's Hospital, Newcastle [n 5 18], and Great Ormond Street Hospital, London [n 5 8]) between October 2012 and September 2016. The median age at transplantation was 1.75 years (range, 0.28-10.3 years). Infants (< _1 year) comprised 34.6% of the cohort. Two patients received a graft from mMUDs: one with an A mismatch and another with DR and DQ mismatches. The median interval between referral and transplantation was 4 months (range, 0.5-16 months; n 5 21). Three patients underwent a second conditioned transplantation for refractory GvHD after matched (10/10) cord blood HSCT. Regarding their first HSCT, 2 of 3 were conditioned. All 3 had skin GvHD, whereas patient 8 also had GvHD affecting the joints and bone marrow, resulting in aplasia, and patient 9 had grade III liver and gut GvHD (biopsy proved). One patient received CD3
1 TCRab (Table I) . Cyclosporine (trough target 50-100 mmol/L) and mycophenolate mofetil were used for 12 and 6 weeks after HSCT, respectively, unless required longer for GvHD. Steroid (1 mg/kg/d) was added for GvHD prophylaxis in patients with refractory GvHD and Omenn syndrome for around 2 weeks after HSCT and then tapered off over the next 4 to 6 weeks. GvHD was graded according to the modified Seattle Glucksberg criteria. 21 All patients received ursodeoxycholic acid, and 5 patients received defibrotide as veno-occlusive disease prophylaxis (1 patient with transaminitis receiving busulfan conditioning, 1 with liver involvement because of hemophagocytic lymphohistiocytosis, 1 with grade III GvHD affecting the liver, and 2 with abnormal liver function test results). All patients received immunoglobulin replacement after HSCT until sustained IgM production was demonstrated.
Viral infections were treated pre-emptively. CMV, EBV, and adenovirus (and human herpesvirus 6 [HHV-6] only in Newcastle) were monitored weekly in the blood by using quantitative PCR. Respiratory (nasopharyngeal aspirate) and gut (feces) viral screens were performed weekly.
Statistical analysis
Data were analyzed as of February 20, 2017 , with STATA version 14.1 software (StataCorp, College Station, Tex). Patients were censored at the time of death or last follow-up. The probabilities of overall survival and event-free survival (EFS) were estimated by using the Kaplan-Meier product limit method. For calculation of EFS, death, disease persistence, and graft failure were considered as events. Primary graft failure was defined as the neutrophil count never reaching 0.5 3 10 9 /L or greater. The probabilities of GVHD, graft failure, viral infections, and transplant-related mortality were calculated as cumulative incidence curves 6 SEs to adjust the analysis for competing risks. Multivariate Cox regression models examining risk factors for GvHD were built with the use of stepwise forward selection, with a P value of .05 or less considered to indicate statistical significance. Variables considered were use of different serotherapy in conditioning, viral reactivation status, and doses of various cells in the graft.
RESULTS
Data on different cell populations in processed grafts are presented in Table II . 15, 16 The median proportion of remaining TCRab T cells in the product after depletion was 0.28% (range, 0.08% to 9.7%). No patients experienced adverse reactions to the infusion of stem cell product.
Neutrophil count recovery occurred in all but 2 conditioned patients at a median of 15 days (range, 10-27 days). One patient experienced primary graft failure, and another died on day 113. The cause of graft failure could not be determined because virology test results were negative and anti-HLA antibodies were present at a low level but were unreactive with the patient's cells. This patient underwent successful retransplantation with CD3
1 depleted stem cells from an mMUD donor. None of the patients required granulocyte colonystimulating factor to achieve engraftment or had secondary graft failure. Patient 8 (Table I) was given buffy coat granulocyte infusions in the peritransplantation period because of pre-existing fungal infection. The median time to platelet engraftment was 9.5 days (range, 0-24 days), which was defined as a platelet count of greater than 20 3 10 9 /L for 7 days (>50 3 10 9 /L for patients with Wiskott-Aldrich syndrome).
Acute graft-versus-host disease (aGvHD) developed in 11 of 23 patients (Table II; 3 cases are excluded: 1 with graft failure and 2 with early death); however, 10 of 11 had only grade I/II skin GvHD and responded to first-line treatment. Two of 10 patients had a recurrence of skin GvHD after cyclosporine discontinuation, and both responded to a short course of steroids. On multivariate analysis, GvHD was not associated with the dose of CD34 1 , T, TCRab 1 , CD19 1 , and NK cells in the graft or the different serotherapy in conditioning or systemic adenovirus or CMV infections.
As of February 2017, 21 of 25 patients are alive and disease free, with a median follow-up of 20.8 months. The probability of overall survival and EFS at 3 years for the whole cohort was 83.9% 6 7.4% (95% CI, 69.3% to 98.4%) and 80.4% 6 7.9% (95% CI, 64.9% to 95.8%), respectively. As of the last follow-up, 76.1% of survivors had full donor chimerism, and 5 patients had high T-cell but mixed myeloid chimerism (2 unconditioned, Table I ).
Transplant-related mortality and morbidities
Transplant-related mortality at 100 days was 11.7% (95% CI, 4.0% to 33.9%), and that at 1 year was 16.1% (95% CI, 6.5% to 39.7%), with 4 deaths. Patient 5 with drug-resistant CMV did not receive serotherapy during conditioning and had grade III skin GvHD requiring prolonged immune suppression, but this patient died from aspergillosis. Two infants (nos. 10 and 21) with disseminated CMV before transplantation died of pulmonary complications soon after transplantation. Patient 12 died 2 months after transplantation because of pulmonary hemorrhage and pulmonary hypertension in the presence of ongoing adenoviremia. Patients going into transplantation with active CMV or adenovirus infection had significantly worse survival in comparison with those with no active viral infection (33.3% vs 100%, P < .0001; Fig 1) .
Early conditioning-related toxicities, such as treosulfan-related skin rash, mucositis, and engraftment syndrome, were mild in most cases. Patient 9 with pre-existing skin GvHD had a severe treosulfan-related rash, which required dressings under sedation. Patients 7, 14, 15, and 21 had severe mucositis. Among conditioned patients, 56.5% required systemic analgesic infusion for at least 72 hours. Patients 7 and 12 had capillary leak syndrome around engraftment and needed oxygen support and diuretics. The most significant noninfectious complications were immune reconstitution inflammatory syndrome (n 5 2) and thrombotic microangiopathy (TMA; n 5 2). Patient 5 with disseminated BCG before transplantation and patient 20 with disseminated enterovirus infection after transplantation had immune reconstitution inflammatory syndrome. 20 TMA developed in patients 7 and 26, who responded to supportive measures with defibrotide 19 in 1 and eculizumab 22 in another. Three patients had features of posterior reversible encephalopathy syndrome, which responded to discontinuation of cyclosporine. None of the patients had veno-occlusive disease. The median number of blood and platelet transfusions after transplantation was 4 (range, 0-29) and 2 (range, 0-46), respectively. Patients with Wiskott-Aldrich syndrome became platelet transfusion independent within 1 week after transplantation. The median day 0 discharge interval in survivors was 86 days (range, 34-327 days).
Viral infections or reactivations after transplantation
Twelve patients had viral infections requiring antiviral therapy within 10 days before transplantation, and 50% were able to clear their virus by day 0. Six children went into transplantation with systemic viremia (CMV, 4; adenovirus, 2), 4 of whom died. Of these, the blood viral PCR titer decreased to less than 2 3 10 3 copies/mL by day 0 in 3 patients with antiviral drugs (1 died and 2 are surviving), and blood viral PCR remained at a higher level of greater than 10 3 10 3 /mL in the remaining patients; all 3 died. Eighteen patients had 26 systemic viral infections or reactivations after transplantation (CMV, 10; adenovirus, 9; HHV-6, 5; EBV, 1; and enterovirus, 1). Among these, 6 infection episodes (33.3%; HHV-6, 3; adenovirus, 2; and EBV, 1) in 3 patients did not result in any complications or require treatment because the titers decreased with immune recovery. The cumulative incidence of any significant viral infection after transplantation (increasing blood titers or disseminated or symptomatic infection) was 59.9% 6 11.1% (Table II) . The median time to clear the virus from blood was 75.5 days (range, 18-210 days). Patients 3, 4, and 14 received CMV-specific cytotoxic T lymphocytes (CTLs) on days 134, 131, and 17, respectively, at a dose of 1 3 10 4 CD3 cells/kg because their viral titers remained greater than 100,000 copies/mL despite antiviral treatment. Patient 19 received adeno-specific CTLs on day 147 as a part of the ASPIRE (adenovirus-specific T cells in pediatric patients after allo-HSCT) trial. Except patient 14, none of these patients had evidence of CMV or adenoviral disease at the time of CTL infusion; however, patients 3 and 4 had CMV retinitis around 2 to 3 weeks after CTL infusion and were managed with intraocular foscarnet along with systemic antivirals. Five patients (3 with CMV and 2 with adenovirus) did not clear viruses after transplantation despite treatment, and 4 of 5 died. To date, no patient has had EBV-related posttransplantation lymphoproliferative disease.
Twelve patients went into transplantation with enteric viral infections (norovirus, 7; adenovirus, 5; and vaccine-associated rotavirus, 3). Five additional patients were found to have viral infections after transplantation (norovirus, 4; enterovirus, 1; and sapovirus, 1). Most of these patients had feeding intolerance and poor weight gain. Of 11 patients with norovirus infection, 9 could clear it at a median of 243 days (range, 122-590 days) after transplantation. All patients had symptomatic improvement before viral clearance from the gut. Patients were managed with enteral feeding (oral or nasogastric tube) or total parenteral nutrition (TPN), as required. Of the total patient population, 80.7% required TPN at some point during the posttransplantation period. Of these, 7 (33.3%) patients required TPN for more than /L for 7 consecutive days without transfusion support; (for patients with WAS, the cutoff was greater than 50 3 10 9 /L for 3 days without transfusion support).
Neutrophil engraftment: absolute neutrophil count greater than 0.5 3 10 9 /L for 3 consecutive days. àATG dose was 15 mg/kg, except for patient 26, in whom a lower dose was used (6 mg/kg). §No specific antiviral treatment given. 80 days after transplantation, and all had gut viral infections (norovirus, 4; rotavirus, 2; and norovirus plus enterovirus, 1).
Immune reconstitution
Cotransfused NK cells were detectable in the first week after transplantation, and NK cell counts remained greater than 200 cells/mL in most patients after day 30. Median time to CD4 recovery (Fig 2) (absolute count > _200 on 2 consecutive tests) was 129 days (range, 79-515) in 20 patients (3 were early deaths, and data for 1 patient are not available). Naive T cells appeared at 4 months after transplantation in most patients (Fig 3) . Median Haplo (23) MUD (27) Haplo (10) mMUD (2) Haplo (24 BW, Body weight; cGvHD, chronic graft-versus-host disease; Haplo, haploidentical; MMF, mycophenolate mofetil; MTX, methotrexate; NA, not applicable; OS, overall survival; Tac, tacrolimus; TRM, transplant-related mortality. *Unconditioned data are excluded. time to B-cell recovery (count > _200 cells/mL on 2 consecutive tests) in all but 2 conditioned patients (n 5 17) was 85 days (range, 41-367 days). The B-cell count of patient 13 remained zero until his death 9 months after HSCT despite good T-cell recovery and 100% donor chimerism. Class-switched memory Bcell (CD27 1
IgD
2 ) testing at 6 months after transplantation showed a median of 1% (range, 0% to 9%) subpopulation of these cells in 14 patients, and the figures at 1 year and 1.5 years were 2% (range, 1% to 4%) and 3% (range, 1% to 5%), respectively. Considering robust absolute B-cell numbers at these time points (Fig 4) , this proportion of class-switched memory B cells heralds good immune recovery. The median time to achieve normal IgM level (>0.5 g/L on 2 separate occasions) in 15 survivors was 97 days (range, 62-187 days) (Fig 4) . Only 5 surviving patients have IgM levels of less than 0.5 g/L; 2 of them are less than 6 months after transplantation. Flow cytometric analyses performed on peripheral blood samples 4 weeks after HSCT showed that gd T cells represented the majority of T cells (mean, 81.5%; range, 32% to 100%). Subsequently, the ab T-cell proportions increased gradually (Fig 5) . A normal ab/gd ratio was reached around 1 year after transplantation.
Long-term follow-up and complications
All surviving patients are doing well. Four patients had autoimmune cytopenias 4 to 17 months after transplantation and responded to steroids, immunoglobulins, or both. One patient has mild chronic renal insufficiency and is receiving antihypertensive therapy. One patient had prolonged (8 months) renal TMA, which has now resolved. Of available data on 17 patients surviving more than 1 year after transplantation, 14 stopped requiring immunoglobulin replacement (indirect evidence of class-switched memory B-cell function) and commenced primary immunizations.
DISCUSSION
We report a 3-year EFS of 80.4% after CD3 
/CD19
1 cell-depleted HSCT in the most diverse group of patients with PIDs reported to date, some of whom historically had poor outcomes with haploidentical donors. 1 Two studies 15, 16 have been published using the same approach for PIDs (Table II) , and the major difference in comparison with our study is the rate of graft failures. Balashov et al 15 showed a high frequency of graft failure, which might be related to the use of only 1 alkylating agent for conditioning in 9 of 10 patients with graft failure. In the study by Bertaina et al, 16 17.4% of patients had graft failure despite receiving 2 alkylating agents, but all were in patients with diseases known to be associated with an increased risk of rejection (thalassemia, osteopetrosis, and severe aplastic anemia). Use of an additional alkylating agent might have helped clear host stem cell niches, as evident by only one case of graft failure in our study. The addition of a second alkylating agent did not seem to result in additional short-term toxicities in both previous studies and the current study in which about half of conditioned patients did not even require systemic analgesia.
Despite using GvHD prophylaxis in our cohort, 47.8% of patients had acute graft-versus-host disease (aGvHD; mild in 10/ 11). It is important to note that 5 of 11 patients had skin GvHD around the time of engraftment (range, day 113 to day 117). We did not perform skin biopsies and have a lower threshold of reporting them as skin GvHD when many centers would report them as engraftment syndrome. In the Italian study only 3 of 23 patients had mild GvHD despite no use of GvHD prophylaxis. Rituximab has been shown to reduce the incidence of aGvHD, J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 4 and rituximab was used in all of their patients; however, both B-cell dose in the graft and use of rituximab were not found to be associated with GvHD on multivariate analysis in our study. However, the number of patients receiving rituximab is small (n 5 6) to derive any definite conclusion. Interestingly, the median dose of B cells in the grafts in the Italian study was a log lower compared with that in our study, although the reason for this is not clear. Although we were able to restrict the TCRab cell dose to less than 1 3 10 5 /kg, it is possible that remaining TCRab or TCRgd cells in the graft might have played a role in the occurrence of aGvHD. Although ab T-cell subsets are known effectors of GvHD, the role of gd T cells in GvHD is unclear, with conflicting results from animal and human studies and some showing a beneficial role in reducing GvHD 24, 25 while others suggest pro-GvHD effects. [26] [27] [28] A recent study 29 showed a lower frequency of naive gd T cells in the peripheral blood of donors corresponding to patients who later had grade II to IV aGVHD.
Interestingly, we saw only skin GvHD in the current study, as in the Italian cohort. 16 A similar trend was noticed in a study in patients with leukemia by Maschan et al 13 : 40% cumulative incidence of isolated skin GvHD in the TCRab-depleted group versus 6% in the matched unrelated transplantation group, although this was not statistically significant. TCRgd cells are found in high concentrations in skin epithelia and gut mucosa under physiologic conditions, and it is possible that TCRgd T cells might have homed into the skin or gut after transplantation, but this does not explain the absence of gut GvHD in our cohort. On the contrary, it is likely that a small amount of TCRab cells in the graft were able to induce mild skin GvHD but did not result in any systemic GvHD. This finding needs further investigation because we have not done subset analysis of infiltrating T cells in GvHD lesions. Moreover, 3 patients underwent transplantation for refractory GvHD, and considering their underlying inflammatory milieu, they had a very high risk of significant GvHD; still, none of them had visceral or severe skin GvHD. This suggests that TCRgd cells are less likely to cause GvHD and that TCRab depletion is a good method to prevent GvHD. With the possible effect of GvHD on the thymus and other detrimental effects on quality of life, any GvHD is undesirable in a patient with nonmalignant disease. Thymic damage caused by GVHD 30 could result in mature medullary epithelial cell depletion and a defect in negative selection, 31 which might lead to a higher risk of chronic GvHD 30 and possibly autoimmune illnesses. Therefore we favored using low-dose cyclosporine. Although we have not seen chronic GvHD in our cohort, 4 patients had autoimmune cytopenias after transplantation, 3 of whom had aGvHD.
It is clear from the evidence that T-cell depletion by means of negative selection (T-cell depletion of the graft) is a better method to reduce the risk of GvHD compared with positive CD34 selection but is associated with an increased risk of graft failure. It is difficult to compare the current study with studies using different ex vivo T-cell depletion strategies for HSCT in children with PIDs because our cohort comprises patients with diverse non-SCID PIDs (which have a higher risk of graft failure vs SCID population) compared with the majority of patients with SCID in previous studies (see Table E1 in this article's Online Repository at www.jacionline.org). [32] [33] [34] However, based on our data and previous reports using TCRab depletion, it is clear that the graft failure rate is low with this technique and that rapid engraftment is achieved in most patients. We suspect that apart from the conditioning, residual TCRgd cells and other immune cells contribute to robust engraftment and a very low rate of graft failure. It has been shown that infusion of activated gd T cells can promote engraftment 35, 36 without causing GvHD, even in the MHC-mismatched situation. 37 Patients going into transplantation with active viral infections had the worst outcomes in our cohort, as shown previously in patients with SCID undergoing HSCT in which infants (>3.5 months of age) with infection had a poor survival in comparison with those with resolved infections or those without prior infection (50% vs 82% vs 90%). 33 One of the deaths in our cohort was at 9 months after transplantation because of aspergillosis resulting from prolonged immune suppression for GvHD. This patient had persistent low-grade CMV viremia at the time of death, which is well known to contribute to both immune suppression 38, 39 and heightened the risk of GvHD 40 requiring immunosuppression, both of which are risk factors for fungal infections. Viral infections in HSCT are known to have unfavorable consequences and increased cost with longer hospital inpatient days. 41 We do not think the use of low-dose cyclosporine in our cohort contributed to the occurrence of viral infections, which is comparable with the data from Bertaina et al 16 (no use of cyclosporine) and the published frequency of viral infections (51.6%) in pediatric patients with nonmalignant illnesses after matched sibling donor or MUD transplantation using reduced-intensity conditioning with regular-dose GvHD prophylaxis. 42 Extensive weekly virology screening, including HHV-6 and enterovirus, might have picked up a higher number of asymptomatic infections in our cohort. An active role of gd T cells in the immune response against CMV 43, 44 has been suggested. Although there might be some beneficial anti-CMV effect from infused gd T cells (as shown by us previously 18 in patient 1), not all patients were able to clear CMV. Of 6 patients with disseminated CMV or adenovirus before transplantation, only 2 survived HSCT despite the use of antivirals. A recent study 45 showed that although the TCRab depletion strategy is associated with high CMV reactivation rates, it does not affect the outcomes of such transplantations.
Similar to previous studies, 34 we have shown robust immune reconstitution 4 months after HSCT. Additionally, cyclosporine was stopped at a median of 4 months (range, 2.5-9 months) after HSCT, and a majority in longer follow-up are no longer receiving immunoglobulins (see Table E1 ). Assuming most children will have a haploidentical donor available, use of this technique will result in a shorter diagnosis-to-transplantation interval, which in turn can lead to fewer pretransplantation infections, which are known to contribute to mortality and morbidity. Availability of donor cells for CTL therapy at a later date will be an additional advantage. 46 The cost of the consumables per CD3 
1 depletion procedure (including apheresis cost) is around £10,000 which is cheaper than procuring an MUD (£15,000-£20,000) or umbilical cord blood (£17,000-£35,000) donor.
We conclude that use of CD3 1 TCRab 1 and CD19 1 depletion for ex vivo processing of mismatched donor grafts ensures a high engraftment rate; good immune reconstitution; low incidence of significant aGvHD, especially visceral GvHD; and acceptable posttransplantation morbidity in children with a range of PIDs, even when used for second HSCT. CD3 
